The primary objective of this study is to evaluate the efficacy and safety of lowering lipoprotein(a) through RNA interference with olpasiran in participants with elevated lipoprotein(a) and at high risk for a first atherosclerotic event.
Principal Investigators Drs. Michelle O’Donoghue and Nicholas Marston discuss the trial.